Pfizer finally fessed up and told the world that it wants to buy British drugmaker AstraZeneca It wasnt a very wellkept secret The New Yorkbased drugmaker   that it approached AstraZeneca in January about getting together AstraZeneca based in London rebuffed the New Yorkers Pfizer executives said Monday that theyre still interested and wish that AstraZenecas management would talk to them Pfizers offer is worth nearly  billion If Pfizer succeeds it would pick up some promising experimental cancer drugs and a business thats otherwise in decline Pfizers management would also be prepared to wield a costcutting axe as they have in the past Pfizer previously gobbled up WarnerLambert Pharmacia and Wyeth Research labs were closed Administrative and sales jobs were cut The savings helped prop up profits Like Pfizer AstraZeneca has seen better days The company thrived by selling purple pills first Prilosec then Nexium for heartburn But generics have hurt Lipitor long Pfizers biggest cash cow has gone generic too Neither companys research labs have covered themselves in glory lately though there are a few hopeful signs So why would Pfizer be willing to pay so much for AstraZeneca One reason would be to get a comfy new tax home Pfizer founded in Brooklyn in  would become a British company by combining with AstraZeneca lowering the new companys tax rate dramatically Theres even a euphemism for this kind of move Its called a   in the trade Pfizers tax rate was about  percent last year In the UK the corporate tax rate stands at  percent and will fall to  percent in  Pfizer CEO Ian Read trained as an engineer and accountant told analysts and investors in a conference call that it is his fiduciary responsibility to maximize value for Pfizer shareholders Despite making a tax move to the UK he said Pfizer would keep its corporate headquarters in the US and retain a listing on the New York Stock Exchange I dont see why theres any conflict with US policy from the deal Read said But as   Matthew Herper   the administration is no fan of tax inversions and has proposed to make them harder to pull off Right now foreign ownership of a company has to hit just  percent to make a tax switch overseas legal The administrations   a threshold of  percent If Pfizer moves ahead with a deal the political pressure to tighten the requirements could mount But Bloomberg reports that Pfizers strategy doesnt look all that risky as far as government action goes This is basically an opportunity to go outside the US and still sell in the US and strip the tax base H David Rosenbloom an attorney at Caplin  Drysdale in Washington and director of the international tax program at New York Universitys law school   Bloomberg If we ever had a legislature in the United States we could do something about this but I dont expect to live that long